Aurion Biotechnologies
Biotechnology company developing regenerative cell therapies for corneal endothelial disease. Focus areas include development and clinical testing of donor-derived corneal endothelial cell therapies, CMC and GMP manufacturing scale-up, quality and analytical testing, regulatory engagement, and global clinical and surgical adoption programs.
Industries
Nr. of Employees
medium (51-250)
Aurion Biotechnologies
Products
AURN001
Investigational combination therapy composed of donor-derived human corneal endothelial cells delivered in a carrier solution containing a rho-kinase inhibitor; intended to rebuild a functional endothelial layer and restore corneal clarity following removal of diseased cells.
AURN001
Investigational combination therapy composed of donor-derived human corneal endothelial cells delivered in a carrier solution containing a rho-kinase inhibitor; intended to rebuild a functional endothelial layer and restore corneal clarity following removal of diseased cells.
Services
On-site and field-facing surgical training programs and clinical site engagement to support investigator technique development and adoption during clinical development.
On-site and field-facing surgical training programs and clinical site engagement to support investigator technique development and adoption during clinical development.
Expertise Areas
- Corneal endothelial cell therapy development
- CMC and GMP cell therapy manufacturing
- Clinical trial management and execution
- Regulatory strategy for regenerative medicine
Key Technologies
- Primary human cell isolation and culture
- Cell therapy formulation and delivery
- Rho-kinase inhibitor–assisted engraftment
- GMP manufacturing for living cell therapies
News & Updates
Report of Phase 1/2 clinical results indicating improvements in best-corrected visual acuity compared with standard of care.
Announcement that the company dosed the first patients in a pivotal Phase 3 study evaluating the lead cell therapy in patients with corneal edema secondary to endothelial dysfunction.
Announcement of completed enrollment in the pivotal Phase 3 ASTRA study for the lead cell therapy program.
Publication describing a prospective randomized trial of corneal endothelial cell therapy in subjects with corneal edema.
Media piece discussing challenges and considerations for scaling manufacturing of living cell therapies.
Report of Phase 1/2 clinical results indicating improvements in best-corrected visual acuity compared with standard of care.
Announcement that the company dosed the first patients in a pivotal Phase 3 study evaluating the lead cell therapy in patients with corneal edema secondary to endothelial dysfunction.
Announcement of completed enrollment in the pivotal Phase 3 ASTRA study for the lead cell therapy program.
Publication describing a prospective randomized trial of corneal endothelial cell therapy in subjects with corneal edema.
Media piece discussing challenges and considerations for scaling manufacturing of living cell therapies.